The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 440-446, August 2010

Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury

  • Leo M. Gazoni, MD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Dustin M. Walters, MD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Eric B. Unger, BS

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Joel Linden, PhD

      Affiliations

    • Department of Medicine, University of Virginia Health System, Charlottesville, Va
    • ,
  • Irving L. Kron, MD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • ,
  • Victor E. Laubach, PhD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • Corresponding Author InformationAddress for reprints: Victor E. Laubach, PhD, Department of Surgery, University of Virginia Health System, PO Box 801359, Charlottesville, VA 22908.

Received 20 August 2009; received in revised form 8 December 2009; accepted 1 March 2010. published online 16 April 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by National Institutes of Health R01HL092953 (to V.E.L. and I.L.K.), National Institutes of Health T32HL007849 (to I.L.K.), and the Roche Organ Transplant Research Foundation (to V.E.L.).

 Disclosures: Drs Linden and Kron were shareholders in Adenosine Therapeutics, LLC, the corporation that provided ATL-313, at the time of the study.

PII: S0022-5223(10)00232-1

doi:10.1016/j.jtcvs.2010.03.002

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 440-446, August 2010

Article Tools

* Image Usage & Resolution